James Loerop - 01 Feb 2026 Form 4/A - Amendment Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role
Chief Business Officer
Signature
/s/ Matthew Rothman, Attorney-in-Fact
Issuer symbol
ACRS
Transactions as of
01 Feb 2026
Net transactions value
-$37,508
Form type
4/A - Amendment
Filing time
05 Feb 2026, 16:38:04 UTC
Date Of Original Report
03 Feb 2026
Previous filing
05 Jan 2026
Next filing
06 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Loerop James Chief Business Officer C/O ACLARIS THERAPEUTICS, INC., 701 LEE ROAD, SUITE 103, WAYNE /s/ Matthew Rothman, Attorney-in-Fact 05 Feb 2026 0001781549

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRS Common Stock Options Exercise +11,250 +7.3% 165,758 01 Feb 2026 Direct F1
transaction ACRS Common Stock Options Exercise +7,500 +4.5% 173,258 01 Feb 2026 Direct F1
transaction ACRS Common Stock Options Exercise +14,750 +8.5% 188,008 01 Feb 2026 Direct F1
transaction ACRS Common Stock Tax liability $37,508 -10,686 -5.7% $3.51 177,322 01 Feb 2026 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACRS Restricted Stock Units Options Exercise $0 -11,250 -100% $0.000000 0 01 Feb 2026 Common Stock 11,250 Direct F1, F3
transaction ACRS Resticted Stock Units Options Exercise $0 -7,500 -50% $0.000000 7,500 01 Feb 2026 Common Stock 7,500 Direct F1, F4
transaction ACRS Restricted Stock Units Options Exercise $0 -14,750 -33% $0.000000 29,500 01 Feb 2026 Common Stock 14,750 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2 The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.
F3 The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2022, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.
F4 The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2023, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.
F5 The shares underlying these restricted stock units vest in four equal installments on the first, second, third and fourth anniversaries of February 1, 2024, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.

Remarks:

This filing amends and restates the Form 4 filed on February 3, 2026 that erroneously reported a February 1, 2025 transaction due to an error with the filing platform.